48 Publications (Page 2 of 2)
2000
Confidence interval criteria for assessment of dose proportionality.
Smith, B P⋅Vandenhende, F R⋅DeSante, K A⋅Farid, N A⋅Welch, P A⋅Callaghan, John T and Forgue, S T
Pharmaceutical research, vol. 17, (no. 10), pp. 1278-83, 2000/Oct. | Journal Article
1999
Olanzapine. Pharmacokinetic and pharmacodynamic profile.
Callaghan, J T⋅Bergstrom, R F⋅Ptak, L R and Beasley, C M
Clinical pharmacokinetics, vol. 37, (no. 3), pp. 177-193, September 1999. | Journal Article
1998
Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men.
Macias, W L⋅Bergstrom, R F⋅Cerimele, B J⋅Kassahun, K⋅Tatum, D E and Callaghan, J T
Pharmacotherapy, vol. 18, (no. 6), pp. 1237-1248. | Journal Article
1997
Disposition and biotransformation of the antipsychotic agent olanzapine in humans.
Kassahun, K⋅Mattiuz, E⋅Nyhart, E⋅Obermeyer, B⋅Gillespie, T⋅Murphy, A⋅Goodwin, R M⋅Tupper, D⋅Callaghan, John T and Lemberger, L
Drug metabolism and disposition: the biological fate of chemicals, vol. 25, (no. 1), pp. 81-93, 1997/Jan. | Journal Article
 
Olanzapine: interaction study with imipramine.
Callaghan, J T⋅Cerimele, B J⋅Kassahun, K J⋅Nyhart, E H⋅Hoyes-Beehler, P J and Kondraske, G V
Journal of clinical pharmacology, vol. 37, (no. 10), pp. 971-978, October 1997. | Journal Article
1990
Disposition in humans of racemic picenadol, an opioid analgesic.
Franz, P M⋅Anliker, S L⋅Callaghan, John T⋅DeSante, K A⋅Dhahir, P H⋅Nelson, R L and Rubin, A
Drug metabolism and disposition: the biological fate of chemicals, vol. 18, (no. 6), pp. 968-73, 1990 Nov-Dec. | Journal Article
 
Relationship between steady-state plasma nizatidine concentrations and inhibition of basal and stimulated gastric acid secretion.
Schneck, D W⋅Callaghan, John T⋅Bergstrom, R F⋅Obermeyer, B D and Offen, W W
Clinical pharmacology and therapeutics, vol. 47, (no. 4), pp. 499-503, 1990/Apr. | Journal Article
 
Role of serum prolactin determination in evaluation of impotent patient.
Foster, Richard S⋅Mulcahy, J J⋅Callaghan, John T⋅Crabtree, R and Brashear, D
Urology, vol. 36, (no. 6), pp. 499-501, 1990/Dec. | Journal Article
 
Secretion of nizatidine into human breast milk after single and multiple doses.
Obermeyer, B D⋅Bergstrom, R F⋅Callaghan, John T⋅Knadler, M P⋅Golichowski, A and Rubin, A
Clinical pharmacology and therapeutics, vol. 47, (no. 6), pp. 724-30, 1990/Jun. | Journal Article
1989
Effect of a leukotriene antagonist, LY171883, on cold air-induced bronchoconstriction in asthmatics.
Israel, E⋅Juniper, E F⋅Callaghan, John T⋅Mathur, Praveen⋅Morris, M M⋅Dowell, A R⋅Enas, G G⋅Hargreave, F E and Drazen, J M
The American review of respiratory disease, vol. 140, (no. 5), pp. 1348-53, 1989/Nov. | Journal Article
1988
Double-blind comparator trials with pinacidil, a potassium channel opener.
Callaghan, John T⋅Goldberg, M R and Brunelle, R
Drugs, vol. 36 Suppl 7, pp. 77-82, 1988. | Journal Article
 
Nizatidine disposition in subjects with normal and impaired renal function.
Aronoff, George R⋅Bergstrom, R F⋅Bopp, R J⋅Sloan, Rebecca and Callaghan, John T
Clinical pharmacology and therapeutics, vol. 43, (no. 6), pp. 688-95, 1988/Jun. | Journal Article
1987
Absorption studies of the H2-blocker nizatidine.
Knadler, M P⋅Bergstrom, R F⋅Callaghan, John T⋅Obermeyer, B D and Rubin, A
Clinical pharmacology and therapeutics, vol. 42, (no. 5), pp. 514-20, 1987/Nov. | Journal Article
 
Nizatidine, and H2-receptor antagonist: disposition and safety in the elderly.
Callaghan, John T⋅Rubin, A⋅Knadler, M P and Bergstrom, R F
Journal of clinical pharmacology, vol. 27, (no. 8), pp. 618-24, 1987/Aug. | Journal Article
1986
Nizatidine, an H2-blocker. Its metabolism and disposition in man.
Knadler, M P⋅Bergstrom, R F⋅Callaghan, John T and Rubin, A
Drug metabolism and disposition: the biological fate of chemicals, vol. 14, (no. 2), pp. 175-82, 1986 Mar-Apr. | Journal Article
1985
Intravenous nizatidine kinetics and acid suppression.
Callaghan, John T⋅Bergstrom, R F⋅Obermeyer, B D⋅King, E P and Offen, W W
Clinical pharmacology and therapeutics, vol. 37, (no. 2), pp. 162-5, 1985/Feb. | Journal Article
1983
Correlation of in vivo and in vitro expression of cell-mediated immunity to mumps skin test antigen.
Petersen, B H⋅Callaghan, John T⋅Steimel, L A and Epinette, W W
The Journal of allergy and clinical immunology, vol. 71, (no. 6), pp. 612-7, 1983/Jun. | Journal Article
 
Delayed hypersensitivity to mumps antigen in humans.
Callaghan, John T⋅Petersen, B H⋅Smith, W C⋅Epinette, W W and Ransburg, R C
Clinical immunology and immunopathology, vol. 26, (no. 1), pp. 102-10, 1983/Jan. | Journal Article
 
Effect of cholestyramine and colestipol on the absorption of phenytoin.
Callaghan, John T⋅Tsuru, M⋅Holtzman, Jordan L and Hunninghake, D B
European journal of clinical pharmacology, vol. 24, (no. 5), pp. 675-8, 1983. | Journal Article
 
Suppression of mitogen-induced lymphocyte transformation in cigarette smokers.
Petersen, B H⋅Steimel, L F and Callaghan, John T
Clinical immunology and immunopathology, vol. 27, (no. 1), pp. 135-40, 1983/Apr. | Journal Article
1982
THE MECHANISM OF PHENYTOIN DOSE-DEPENDENCY (Dissertation)
Callaghan, John T (1982).
1981
Clinical response of patients with galactorrhea to pergolide, a potent, long-acting dopaminergic ergot derivative.
Callaghan, John T⋅Cleary, R E⋅Crabtree, R and Lemberger, L
Life sciences, vol. 28, (no. 1), pp. 95-102, 1981/Jan/5. | Journal Article
1980
Pergolide, a potent long-acting dopamine-receptor agonist.
Lemberger, L⋅Crabtree, R and Callaghan, John T
Clinical pharmacology and therapeutics, vol. 27, (no. 5), pp. 642-51, 1980/May. | Journal Article